Keyphrases
Activated Macrophages
10%
All-cause Mortality
16%
Antiplatelet Therapy
12%
Atherosclerotic CVD
8%
Blood Pressure
12%
C-Rel
10%
Cardiovascular Disease
50%
Cardiovascular Effects
37%
Cardiovascular Mortality
16%
Cardiovascular Risk Reduction
12%
Causes of Mortality
12%
Clinical Benefit
8%
Clinical Outcomes
50%
Cochrane Central Register of Controlled Trials
8%
Coronary Revascularization
16%
Current Recommendations
12%
Diabetes Disease
50%
Diabetes Management
75%
Diabetes Review
12%
Disease Process
12%
Embase
8%
Endocrine Disorders
50%
Extracted Data
8%
Glucose-lowering Drugs
37%
Glycemic Control
12%
High Cardiovascular Risk
12%
High Risk
8%
Hypertensive
12%
IL-12 Production
50%
Interleukin-12 (IL-12)
25%
Landmark Trials
12%
LDL Levels
12%
Lipid Management
50%
Lipid-lowering Agents
12%
Major Adverse Cardiovascular Events
16%
MEDLINE
8%
Meta-analysis
50%
Myocardial Infarction
16%
NF-B
50%
Nuclear Translocation
50%
Overexpression
10%
Pathophysiology
12%
Patients with Diabetes
37%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
50%
Randomized Clinical Trial
50%
Randomized Controlled Trial
8%
Risk Reduction
12%
Statins
12%
Therapeutic Strategies
12%
Tristetraprolin
50%
Medicine and Dentistry
All Cause Mortality
16%
Antihypertensive Agent
8%
Antiplatelet
8%
Apoplexy
16%
Blood Pressure
8%
Cardiovascular Disease
66%
Cardiovascular Mortality
16%
Cardiovascular Risk
16%
Cardiovascular System
25%
Diabetes
100%
Disease Process
8%
Endocrine Disease
50%
Glycemic Control
8%
Heart Muscle Revascularization
16%
Hypolipidemic Agent
8%
Independent Reviewer
8%
Meta-Analysis
50%
Myocardial Infarction
16%
Pathophysiology
8%
Patient with Diabetes
8%
Proprotein Convertase 9
50%
Randomized Clinical Trials
50%
Randomized Controlled Trial
8%
Risk Reduction
16%
Statin
8%
